Metro Healthcare Berhad Announces Proposed Bonus Issue of Warrants: What Investors Need to Know
Key Highlights of the Announcement
- Bonus Issue of Warrants: Metro Healthcare Berhad (“Metro” or “the Company”) has proposed a bonus issue of free warrants on the basis of 1 warrant for every 4 existing ordinary shares held by shareholders on the entitlement date to be announced later.
- Potential Size: Up to 244,726,250 free warrants may be issued, based on the current share capital of 978,905,000 shares as at 21 April 2026. If all warrants are exercised, the issued share capital could expand to 1,223,631,250 shares.
- Rationale: The move is aimed at rewarding shareholders, providing alternative trading instruments, strengthening the capital base, and offering a future fundraising avenue without immediate dilution or interest cost.
- Price Sensitivity: The eventual exercise price of the warrants will be fixed at a discount or premium of up to 20% of the 5-day volume-weighted average price (VWAP) before the fixing date, with an illustrative exercise price of RM0.20 per warrant currently assumed.
Detailed Terms of the Proposed Bonus Issue of Warrants
- Cost to Shareholders: The warrants will be issued at no cost to entitled shareholders.
- Trading and Listing: Both the warrants and the new shares arising from their exercise will be listed on the ACE Market of Bursa Malaysia Securities.
- Warrants Exercise Period: Each warrant entitles the holder to subscribe for one new share at any time within five years from the date of issuance.
- Form of Warrants: The warrants will be credited into the Securities Accounts of the recipients and will be tradable in board lots (100 warrants per lot, subject to Bursa rules).
- Adjustments: The number and exercise price of the warrants may be adjusted in accordance with the provisions of the Deed Poll, to be executed by the Company.
- Entitlement: Warrant holders will not be entitled to dividends, voting rights, or other distributions until the warrants are exercised into new shares.
- Winding-up Provisions: In the event of a members’ voluntary winding up, warrant holders may exercise their rights within six weeks after the relevant resolution or court order.
Financial Impact and Shareholder Considerations
- No Immediate Dilution: The bonus issue itself does not immediately dilute existing shareholdings; dilution occurs only upon exercise of the warrants.
- Potential Fundraising: If all warrants are exercised at RM0.20 each, Metro could raise up to RM48.9 million over the next five years. Proceeds would be used for working capital, capital expenditure, and possibly debt repayment.
- Impact on Earnings Per Share (EPS): There will be an EPS dilution as more shares are issued upon exercise of the warrants, though the exact timing and amount depend on actual warrant exercises.
- Net Assets (NA): Full exercise of the warrants would increase NA per share from RM0.08 to RM0.10, and total shareholders’ funds from RM75.1 million to RM123.8 million, with no borrowings post-exercise.
- Substantial Shareholders: The major shareholders and their percentage holdings will not be significantly diluted assuming all warrants are exercised, as they receive proportional entitlements.
- No Other Recent Fundraising: The company confirmed no other fundraising exercises in the past 12 months.
Strategic and Industry Context
- Favourable Industry Outlook: The Malaysian economy is growing steadily, and the healthcare industry is receiving increased public and private investment. The Government’s focus on healthcare and medical tourism is expected to benefit private providers like Metro.
- Metro’s Positioning: Metro operates primarily in fertility, obstetrics & gynaecology, and pediatric segments, which are expected to see continued demand due to demographic trends, higher maternal age, rising infertility rates, and greater awareness of assisted reproductive treatments.
- Growth Initiatives: Metro is investing in new facilities, including a 120-bed multi-disciplinary specialist hospital in Bandar Rimbayu, Selangor, which could contribute to revenue growth but involves execution and ramp-up risks.
- Risks: The group faces challenges such as rising operating costs, competition, reliance on medical professionals, and regulatory changes.
Timetable and Approvals
- Approvals Needed: The proposal is subject to approval from Bursa Securities (for the listing and quotation of the warrants and new shares) and shareholders at an upcoming Extraordinary General Meeting (EGM).
- Expected Completion: Subject to approvals, the bonus issue of warrants is expected to be completed by the third quarter of 2026.
Key Takeaways for Investors
- Price Sensitivity: The bonus issue of warrants is a significant corporate action that could enhance trading liquidity, provide upside leverage if the company’s share price rises, and potentially lead to a substantial capital base increase if warrants are exercised in the future.
- Long-Term Capital Strengthening: Investors should monitor the exercise price announcement and the company’s growth trajectory as this fundraising mechanism could facilitate Metro’s future expansion without immediate shareholder dilution or interest costs.
- EGM Participation: Shareholders should take note of the forthcoming EGM to vote on the proposal, as it may impact their future value and rights in the company.
Disclaimer
This article is intended for informational purposes only and does not constitute investment advice. Investors are advised to perform their own due diligence and consult their financial advisors before making any investment decisions related to Metro Healthcare Berhad. The information provided is based on the company’s official announcement and may be subject to change pending regulatory and shareholder approvals.
